Portal de Periódicos da CAPES

Apd in paget's disease of bone role of the mononuclear phagocyte system?

1980; Wiley; Volume: 23; Issue: 10 Linguagem: Inglês

10.1002/art.1780231018

1529-0131

O. L. M. Bijvoet, W. B. Frijlink, Kon‐Siong G. Jie, H. Der Van Linden, C J Meijer, Hindrik Mulder, H. C. Van Paassen, Pieter H. Reitsma, J. te Velde, Esther de Vries, J. P. Der Van Wey,

Spondyloarthritis Studies and Treatments

Arthritis & RheumatismVolume 23, Issue 10 p. 1193-1204 ArticleFree to Read Apd in paget's disease of bone role of the mononuclear phagocyte system? O. L. M. Bijvoet MD, Corresponding Author O. L. M. Bijvoet MD Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Department of Clinical Endocrinology and Metabolism, University Hospital, 2333 AA, Leiden, The NetherlandsSearch for more papers by this authorW. B. Frijlink, W. B. Frijlink Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorK. Jie, K. Jie Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorH. Der Van Linden, H. Der Van Linden Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorC. J. L. M. Meijer, C. J. L. M. Meijer Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorH. Mulder, H. Mulder Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorH. C. Van Paassen, H. C. Van Paassen Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorP. H. Reitsma, P. H. Reitsma Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorJ. Te Velde, J. Te Velde Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorE. De Vries, E. De Vries Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorJ. P. Der Van Wey, J. P. Der Van Wey Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this author O. L. M. Bijvoet MD, Corresponding Author O. L. M. Bijvoet MD Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Department of Clinical Endocrinology and Metabolism, University Hospital, 2333 AA, Leiden, The NetherlandsSearch for more papers by this authorW. B. Frijlink, W. B. Frijlink Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorK. Jie, K. Jie Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorH. Der Van Linden, H. Der Van Linden Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorC. J. L. M. Meijer, C. J. L. M. Meijer Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorH. Mulder, H. Mulder Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorH. C. Van Paassen, H. C. Van Paassen Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorP. H. Reitsma, P. H. Reitsma Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorJ. Te Velde, J. Te Velde Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorE. De Vries, E. De Vries Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this authorJ. P. Der Van Wey, J. P. Der Van Wey Clinical Investigation Unit of the Department of Clinical Endocrinology and Metabolism and Departments of Rheumatology and Pathology, University Hospital, 2333 AA, Leiden, The Netherlands.Search for more papers by this author First published: October 1980 https://doi.org/10.1002/art.1780231018Citations: 103AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Reference 1 Schenk R, Merz WA, Mühlbauer R, Russell RGG, Fleisch H: Effect of ethane-l-hydroxy-l, l-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calc Tiss Res 11: 196– 214, 1973 2 Bijvoet OLM, Jansen AP: Thyrocalcitonin in Paget's disease. Lancet ii: 471– 472, 1976 3 Woodhouse NJY, Reiner M, Bordier P, Kalu DN, Fisher MT, Foster GV, Joplin GF, MacIntyre I: Human calcitonin in the treatment o Paget's bone disease. Lancet 1: 1139– 1143, 1971 4 Evans IMA, Banks L, Doyle FH, Joplin GF, Pennock J, Stevenson JC, MacIntyre I: Paget's disease of bone: the effect of stopping long term human calcitonin and recommendations for future treatment. Metab Bone Dis Rel Res 2: 87– 91, 1980 5 Khairi MRA, Altman RD, de Rosa GP, Zimmermann J, Schenk RK, Johnston CC: Sodium etidronate in the treatment of Paget's disease of bone: a study of long term results. Ann Intern Med 87: 656– 663, 1977 6 Frijlink WB, Bijvoet OLM, Te Velde J, Heynen G: Treatment of Paget's disease with (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate (APD). Lancet i: 799– 803, 1979 7 Smith R, Russell RGG, Bishop M: Diphosphonates and Paget's disease of bone. Lancet i: 945– 947, 1971 8 Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sankey RR: Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289: 1379– 1384, 1973 9 Hosking DJ, Bijvoet OLM, Van Aken J, Will EJ: Paget's bone disease treated with diphosphonate and calcitonin. Lancet i: 615– 617, 1975 10 Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Edouard C, Vignon E. Mathieu L. Trechsel U: Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet ii: 489– 492, 1979 11 Bijvoet OLM, Hosking DJ, Lemkes HHPJ, Reitsma PH, Frijlink W: Development in the treatment of Paget's disease, Endocrinology of Calcium Metabolism. Edited by RV Talmage. Amsterdam, Excerpta Medica, 1977, pp 48– 54 12 Russell RGG, Fleisch H: Pyrophosphate and diphosphonales, The Biochemistry and Physiology of Bone. Vol IV. Edited by GH Bourne. New York, Academic Press, 1976, pp 61– 104 13 Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, Van der Wee-Pals: Kinetic studies of bone and mineral metabolism during treatment with (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate (APD) in rats. Calcif Tiss Intern in press, 1980 14 Russell RGG, Kislig AM, Casey PA, Fleisch H, Thornton J, Schenk R, Williams DA: Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone. Calc Tiss Res 11: 179– 195, 1973 15 Gasser AB, Morgan DB, Fleisch HA, Richelle LJ: The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43: 31– 45, 1972 16 Miller Sc, Jee WSS: The comparative effects of dichloromethylene diphosphonate (Cl2MDP) and ethane-l-hydroxy-l,l-diphosphonate (EHDP) on growth and modelling of the rat tibia. Calc Tiss Res 23: 207– 214, 1977 17 Bijvoet OLM, Hosking DJ, Frijlink WB, Te Velde J, Vellenga CJLR: Treatment of Paget's disease with combined calcitonin and diphosphonate (EHDP). Metab Bone Dis Rel Res 1: 251– 261, 1978 18 Reitsma PH, Bijvoet OLM, Frijlink WB, Vismans FJFE, van Breukelen FJM: Pharmacology of disodium (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate, Proceedings of the Fourth International Workshop on Phosphate and Other Minerals. Edited by SG Massry. New York, Plenum Press, 1980 19 Loutit JF, Nisbet NW: Resorption of bone. Lancet ii: 26– 28, 1979 20 Coccia AF, Krivit W, Cervenka J, Clawson C, Kersey JH, Kim TH, Nesbit ME, Ramsay NKC, Warkentin PJ, Teitelbaum SL, Kahn RJ, Brown DM: Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 302: 701– 708, 1980 21 Miller SC, Jee WSS, Kimmel DB, Woodbury L: Ethane-l-hydroxy-l, l-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calc Tiss Res 22: 243– 245, 1977 22 Evans RA, Baylink DJ, Wergedal J: The effects of two diphosphonates on bone metabolism in the rat. Metab Bone Dis Rel Res 2: 39– 48, 1979 23 Marks SC: Pathogenesis of osteopetrosis in the ia rat: reduced resorption due to reduced osteoclast function. Am J Anat 138: 165– 190, 1973 24 Vismans FJFE, Frijlink WB, te Velde J, Bijvoet OLM: Unpublished observations 25 Mundy GR, Varani J, Orr W, Gondek MD, Ward PA: Resorbing bone is chemotactic for monocytes. Nature 275: 132– 135, 1978 26 Olsen ChE, Wahl S, Wahl LM, Sandberg AL, Mergenhagen SE: Immunological defects in osteopetrotic mice, Mechanisms of Localized Bone Loss. Edited by JE Horton, TM Tarpley, WF Davis. Washington DC, Information Retrieval Inc, 1977, pp 389– 398 27 Walker DG: Spleen cells transmit osteopetrosis in mice. Science 190: 785– 787, 1975 28 Yoneda T, Mundy GR: Monocytes regulate osteoclast-activating factor production by releasing prostaglandins. J Exp Med 150: 338– 350, 1979 29 Walker DG: Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190: 784– 785, 1975 30 Allison AC: Macrophage activation and nonspecific immunity. Int Rev Exp Pathol 18: 303– 346, 1978 31 Francis MB, Flora L, King WR: The effects of disodium ethane-l-hydroxy-l, l-diphosphonate in adjuvant induced arthritis in rats. Calc Tiss Res 9: 109– 121, 1972 32 Flora L: Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22: 340– 346, 1979 33 Smith R, Russell RGG, Bishop M: Paget's disease of bone: experience with a diphosphonate (disodium etidronate) in treatment. Q J Med New Series 42: 235– 256, 1974 34 Kantrowitz FG, Byrne MH, Schiller AL, Krane SM: Clinical and biochemical effects of diphosphonate in Paget's disease of bone. Arthritis Rheum 18: 407, 1975 35 Finerman GAM, Gonick HC, Smith RK, Mayfield JM: Diphosphonate treatment of Paget's disease. J Clin Orthop Rel Res 120: 115– 124, 1976 36 Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP: Calcitonin or diphosphonates for osteolytic Paget's disease? Lancet i: 374, 1980 37 Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, Kammermans S, Ryan K, Kunigonis M, Bohne W: Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 44: 96– 106, 1977 38 Reitsma PH, Bijvoet OLM: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma, correspondence. N Engl J Med 303: 162– 163, 1980 39 Heynen G: In preparation 40 Beisel WR, Pekarek RS, Wannemacher RW: Homeostatic mechanisms affecting plasma zinc levels in acute stress, Trace Elements in Human Health and Disease. Vol 1. Edited by AS Prasad, D Oberleas. New York, Academic Press, 1976, pp 87– 106 41 McConnell I: Structure and function of lymphoid tissue, The Immune System. Edited by MJ Hobarth, I McConnel. Oxford, Blackwell 1978, pp 206– 223 42 Bernier GM, Fanger MW: Synthesis of β2-microglobulin by stimulated lymphocytes. J Immunol 109: 407– 409, 1972 43 Bonta IL, Parnham MJ: Prostaglandins and chronic inflammation. Biochem Pharmacol 27: 1611– 1623, 1978 44 Parnham MJ, Bonta IL, Adolfs MJP: Interactions between prostaglandin E and cyclic nucleotides in chronic inflammatory disease, Perspectives in Inflammation. Edited by DA Willoughby, JP Girond, GP Velo. Lancaster, MTP Press, 1977, pp 279– 287 45 Rebel A, Malkani A, Basle M, Bregeon C: Osteoclast ultrastructure in Paget's disease. Calcif Tiss Res 20: 187– 199, 1976 46 Singer F, Mills BG, Terry R: Bone resorbing cells in Paget's disease, Mechanisms of Localized Bone Loss. Edited by JE Horton, TM Tarpley, WF Davis. Washington DC, Information Retrieval Inc, 1977, pp 365– 374 47 Haslhofer L: Die Pagetschen Knockenkrankheit, Handbuch der speziellen pathologischen Anatomie und Histologie. Edited by O Lubarsch, F Henke. Berlin, Julius Springer Verlag, 1937, pp 551– 616 48 de Vries JE, Caviles AP, Bont WS, Mendelsohn J: The role of monocytes in human lymphocyte activation by mitogens. J Immunol 122: 1099– 1107, 1979 49 Rinehart JJ, Orser M, Kaplan ME: Human monocyte and macrophage modulation of lymphocyte proliferation. Cell Immunol 44: 131– 143, 1979 50 de Vries E, Lafeber GJM, van der Wey JP, Buysen AC, Leijk PCJ, Cats A: Pokeweed mitogen induced lymphocyte proliferation: the effect of stimulation on mononuclear cells. J Immunol, in press, 1980 51 de Vries E, van de Putte EBL, Lafeber GJM, van Buysen-Nutters AC, de Vetten-van der Hulst HLM: Morphological differences in the interactions between human mononuclear cells and coated or uncoated sheep red blood cells: a freeze-etch study of different types of rosettes. Cell Tiss Res 168: 79– 88, 1976 52 van Breukelen FJM, Bijvoet OLM, van Oosterom AT: Inhibition of osteolytic bone lesions by (3-amino-l-hydroxypropylidene)-l,l-bisphosphonate (APD). Lancet i: 803– 805, 1979 53 Minne H, Klü H, Ziegler R, Bijvoet OLM: Treatment of paraneoplastic hypercalcemia in Walker tumor bearing rats with the diphosphonate APD. Mineral Electrolyte Metab 2: 251– 252, 1979 Citing Literature Volume23, Issue10October 1980Pages 1193-1204 ReferencesRelatedInformation